Andrew Huberman· PhD
So, our lab kept working and working, and that's when Michael, the patient with angiosarcoma came to us back in 2016, and we found out that this drug for melanoma could actually treat his angiosarcoma cancer.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So, our lab kept working and working, and that's when Michael, the patient with angiosarcoma came to us back in 2016, and we found out that this drug for melanoma could actually treat his angiosarcoma cancer.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
The other thing it did specifically for Michael is that it has put him into now a nine-year remission.